title: [Indications and results of infliximab in Crohn's disease].
abstract: Infliximab is a chimeric monoclonal antibody to tumor necrosis factor a. Induction therapy with infliximab is indicated for treatment of refractory Crohn's disease and for reduction in the number of draining fistulas in fistulizing Crohn's disease. Indications for maintenance therapy with infliximab include maintenance of remission in active Crohn's disease who responded to initial induction therapy with infliximab and maintenance of fistula improvement who responded to initial therapy with infliximab. Side effects of infliximab are infusion reactions, immunogenicity, induction of DNA antibodies and infection complications including tuberculosis.
authors.affiliation: Service de Gastro-entérologie A, Hôpital la Rabta, Tunis.
authors.forename: Sami
authors.initials: S
authors.lastname: Karoui
authors.forename: Jalel
authors.initials: J
authors.lastname: Boubaker
authors.forename: Azza
authors.initials: A
authors.lastname: Filali
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D010919:Placebos; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors; D014376:Tuberculosis / Q000150:complications / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D010919:Placebos; D000069285:Infliximab